A social significance of the pharmacogenetic testing in Ukraine on the example of the CYP2B6 gene participating in the nicotine metabolism

M. M. Kobets, O. V. Filiptsova, Yu. M. Kobets

Abstract


The study of the pharmacogenetic testing in Ukraine on the example of the gene CYP2B6 participating in the nicotine metabolism is currently topical and socially significant problem.
Aim. To determine the potential sample among the residents of Ukraine, for which the therapeutic effect of the treatment of nicotine addiction with bupropion will be the most effective considering polymorphism of the CYP2B6 gene.
Materials and methods. Genotyping of the participants in the study with respect to CYP2B6 polymorphism (rs3745274) was carried out using a polymerase chain reaction. In addition to genotyping, the survey participants filled in questionnaires that reflected their socio-demographic data, as well as the lifestyle, duration and frequency of smoking.
Results and discussion. In the course of the studies conducted it has been found that approximately 7 % of the population has a genetic variant of CYP2B6 predisposing to smoking. The same persons are a potential target audience for conducting the personalized therapy.
Conclusions. Prior the pharmacotherapy it is advisable to conduct the pharmacogenetic testing, which will reduce the cost of therapy and the risk of side effects in the future.


Keywords


Pharmacogenetic testing; CYP2B6 gene; nicotine addiction; Ukraine

Full Text:

PDF

References


Sychev, D. A. (2011). Farmakogeneticheskoe testirovanie: klinicheskaia interpretatciia rezultatov. Moscow, 88.

Sychev, D. A., Ignatev, I. V., Ramenskaia, G. V., Kukes, V. G. (2007). Klinicheskaia farmakogenetika. Moscow: GEOTAR–MEDIA, 248.

Verde, Z., Santiago, C., Rodríguez González–Moro, J. M., de Lucas Ramos, P., López Martín, S., Bandrés, F., Gómez–Gallego, F.

(2011). “Smoking Genes”: A Genetic Association Study. PLoS ONE, 6 (10), e26668. doi: 10.1371/journal.pone.0026668

Website of the World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs339/en/

Tomaz, P. R. X., Santos, J. R., Issa, J. S., Abe, T. O., Gaya, P. V., Krieger, J. E., Santos, P. C. J. L. (2015). CYP2B6 rs2279343 polymorphism

is associated with smoking cessation success in bupropion therapy. European Journal of Clinical Pharmacology, 71 (9),

–1073. doi: 10.1007/s00228–015–1896–x

Koegelenberg, C. F. N., Noor, F., Bateman, E. D., van Zyl–Smit, R. N., Bruning, A., O’Brien, J. A., Irusen, E. M. (2014). Efficacy of

Varenicline Combined With Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation. JAMA, 312 (2), 155.

doi: 10.1001/jama.2014.7195

Elrashidi, M. Y., Ebbert, J. O. (2014). Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opinion on Emerging

Drugs, 19 (2), 243–260. doi: 10.1517/14728214.2014.899580

Piné–Abata, H., McNeill, A., Murray, R., Bitton, A., Rigotti, N., Raw, M. (2013). A survey of tobacco dependence treatment services in

countries. Addiction, 108 (8), 1476–1484. doi: 10.1111/add.12172

Elbe, D., Bezchlibnyk–Butler, K. Z., Virani, A. S., Procyshyn, R. M. (2014). Pharmacotherapy for Nicotine/Tobacco Use Dependence.

Clinical Handbook of Psychotropic Drugs for Children and Adolescents, 3d. Hogrefe Publishing, 329.

Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Pinto, A., Hawk, L., Epstein, L. (2002). Pharmacogenetic investigation of smoking

cessation treatment. Pharmacogenetics, 12 (8), 627–634. doi: 10.1097/00008571–200211000–00007

Filiptsova, O. V., Kobets, M. N., Kobets, Yu. N, Timoshyna, I. A. (2017). SNP polymorphism of CYP1A2 (rs762551) and CYP2B6

(rs3745274) in the Ukrainian population: a pilot study. From genomics to therapy. Barcelona, Spain, 80.

Walsh, P. S., Metzger, D. A., Higuchi, R. (1991). Chelex 100 as a medium for extraction of DNA for PCR–based typing from forensic

material. BioTechniques, 10, 506–513.

Masebe, T. M., Bessong, P. O., Nwobegahay, J., Ndip, R. N., Meyer, D. (2012). Prevalence of MDR1 C3435T and CYP2B6 G516T

Polymorphisms among HIV–1 Infected South African Patients. Disease Markers, 32 (1), 43–50. doi: 10.1155/2012/453479

Chislo kurilshchikov v Ukraine stabilizirovalos na urovne 24%. Available at: https://zn.ua/UKRAINE/chislo–kurilschikov–v–ukraine–

stabilizirovalos–na–urovne–24–202795_.html

Spravochnaia aptek. Available at: https://www.spravka–apteka.com.ua/ziban–price/

All tests – take tests in medical laboratory “Synevo”. Available at: https://www.synevo.ua/en/analizy/vse–analizy/


GOST Style Citations


1. Сычев, Д. А. Фармакогенетическое тестирование : клиническая интерпретация результатов : реком. для практикующих врачей /
Д. А. Сычев. – М., 2011. – 88 с.

2. Клиническая фармакогенетика / Д. А. Сычев, И. В. Игнатьев, Г. В. Раменская, В. Г. Кукес ; под ред. В. Г. Кукеса, Н. П. Бочкова. –
М. : ГЭОТАР–МЕДИА, 2007. – 248 с.

3. ‘Smoking genes’: a genetic association study / Z. Verde, C. Santiago, J. M. Rodriguez Gonzalez–Moro et al. // PLoS One. – 2011. – Vol. 6,
Issue 10. – e26668 p. doi: 10.1371/journal.pone.0026668

4. Website of the World Health Organization. – Available at : http://www.who.int/mediacentre/factsheets/fs339/en/

5. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy / P. R. X. Tomaz, J. R. Santos,
J. S. Issa et al. // Eur. J. Clin. Pharmacol. – 2015. – Vol. 71, Issue 9. – P. 1067–1073. doi: 10.1007/s00228–015–1896–x

6. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation : a randomized clinical
trial / C. F. Koegelenberg, F. Noor, E. D. Bateman et al. // JAMA. – Vol. 312, Issue 2. – 155 p. – doi: 10.1001/jama.2014.7195

7. Elrashidi, M. Y. Emerging drugs for the treatment of tobacco dependence : 2014 update / M. Y. Elrashidi, J. O. Ebbert // Expert opinion
on emerging drugs. – 2014. – Vol. 19, Issue 2. – P. 243–260. doi: 10.1517/14728214.2014.899580

8. A survey of tobacco dependence treatment services in 121 countries / H. Pine–Abata, A. McNeill, R. Murray et al. // Addiction. – 2013. –
Vol. 108, Issue 8. – P. 1476–1484. doi: 10.1111/add.12172

9. Pharmacotherapy for Nicotine/Tobacco Use Dependence / D. Elbe, K. Z. Bezchlibnyk–Butler, A. S. Virani, R. M. Procyshyn // Clinical
Handbook of Psychotropic Drugs for Children and Adolescents. – 3-d. – Hogrefe Publishing, 2014. – 329 p.

10. Pharmacogenetic investigation of smoking cessation treatment / С. Lerman, P. G. Shields, E. P. Wileyto et al. // Pharmacogenetics. –
2002. – Vol. 12, Issue 8. – P. 627–634. doi: 10.1097/00008571–200211000–00007

11. SNP polymorphism of CYP1A2 (rs762551) and CYP2B6 (rs3745274) in the Ukrainian population : a pilot study / O. V. Filiptsova,
M. N. Kobets, Yu. N. Kobets, I. A. Timoshyna // From genomics to therapy. – Barcelona, Spain, 2017. – 80 p.

12. Walsh, P. S. Chelex 100 as a medium for extraction of DNA for PCR–based typing from forensic material / P. S. Walsh, D. A. Metzger,
R. Higuchi // BioTechniques. – 1991. – Vol. 10. – P. 506–513.

13. Prevalence of MDR1 C3435T and CYP2B6 G516T Polymorphisms among HIV–1 Infected South African Patients / T. M. Masebe,
P. O. Bessong, J. Nwobegahay et al. // Dis Markers. – 2012. – Vol. 32, Issue 1. – P. 43–50. doi: 10.1155/2012/453479

14. Число курильщиков в Украине стабилизировалось на уровне 24 %. – Режим доступа: https://zn.ua/UKRAINE/chislo–kurilschikov–
v–ukraine–stabilizirovalos–na–urovne–24–202795_.html

15. Справочная аптек. – Режим доступа: https://www.spravka–apteka.com.ua/ziban–price/

16. All tests – take tests in medical laboratory «Synevo». – Available at: https://www.synevo.ua/en/analizy/vse–analizy/





DOI: https://doi.org/10.24959/nphj.18.2204

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Vìsn. farm.

ISSN 2415-8844 (Online), ISSN 1562-7241 (Print)